Učitavanje...

Gefitinib suppresses cervical cancer progression by inhibiting cell cycle progression and epithelial-mesenchymal transition

Cervical cancer (CC) is the second most common malignant cancer among women. Gefitinib was one of the first-generation epidermal growth factor receptor-tyrosine kinase inhibitors in clinical trials. However, the underlying mechanism of gefitinib in regulating CC progression remains unknown. In the c...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Exp Ther Med
Glavni autori: Zheng, Jianyun, Yu, Jianxin, Yang, Min, Tang, Li
Format: Artigo
Jezik:Inglês
Izdano: D.A. Spandidos 2019
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6676113/
https://ncbi.nlm.nih.gov/pubmed/31410143
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2019.7754
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!